HUTCHMED (China) - ADR Peer Comparison
$14.11
$2.07
(17.19%)
As on 03-Sep-2026 16:24EDT
Market cap
$2,152 Mln
Revenue (TTM)
$549 Mln
P/E Ratio
123.8
P/B Ratio
1.7
Div. Yield
0 %
Edit
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,152 | 2,928 | 2,262 | 851 | 828 |
Revenue ($ Mln) |
549 | 450 | 120 | -- | 366 |
Net Profit ($ Mln) |
17.88 | -188.21 | -57.50 | -175.85 | 9.27 |
Net Margin (%) |
3.26 | -41.86 | -144.33 | -- | 2.53 |
RoE (%) |
1.43 | -28.46 | -9.86 | -106.84 | 3.39 |
Price to Earnings |
123.80 | -- | -- | -- | 83.57 |
Price-To-Book |
1.71 | 4.96 | 4.15 | 5.68 | 3.10 |
Income Statement ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
549.12 | 449.61 | 17.20 | 0.00 | 366.45 |
|
Cost of Revenue
|
548.01 | 195.71 | 5.13 | 12.78 | 49.36 |
|
Gross Profit
|
212.72 | 269.08 | 12.07 | -17.67 | 330.63 |
|
Operating Expenses
|
35.89 | 517.90 | 74.51 | 176.86 | 304.74 |
|
Operating Profit (EBIT)
|
-34.78 | -264.00 | -62.44 | -181.14 | 12.35 |
|
Other Income
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
Profit before Tax
|
20.08 | -190.72 | -101.81 | -178.93 | 15.84 |
|
Provision for Tax
|
1.66 | -2.51 | 0.33 | -3.09 | 6.57 |
|
Profit after Tax (Net Income)
|
17.88 | -188.21 | -102.14 | -175.85 | 9.27 |
|
Minority Interest
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
Liabilities ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,260.78 | 607.04 | 597.44 | 160.40 | 270.49 |
|
Minority Interest
|
0.00 | 0.00 | -- | 0.00 | 0.00 |
|
Non-Current Liabilities
|
186.25 | 39.17 | 84.62 | 8.50 | 104.25 |
|
Current Liabilities
|
275.21 | 428.58 | 102.63 | 54.30 | 93.25 |
|
Total Liabilities
|
1,753.10 | 1,172.38 | 784.68 | 233.72 | 499.81 |
Assets ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
183.02 | 160.76 | 580.33 | 21.30 | 187.30 |
|
Current Assets
|
1,553.41 | 914.04 | 204.35 | 201.90 | 280.69 |
|
Total Assets
|
1,753.10 | 1,172.38 | 784.68 | 233.72 | 499.81 |
|
Total Debt*
|
94.51 | 254.58 | 128.16 | 21.00 | 113.30 |
|
Net Current Assets
|
0.00 | 485.45 | 101.72 | 147.60 | 187.44 |
Cashflow ($ Mln)
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-64.66 | -150.79 | -49.95 | -121.18 | 54.71 |
|
Cash Flow from Investing Activities
|
-29.41 | 307.87 | 0.12 | -1.37 | 26.25 |
|
Cash from Financing Activities
|
7.84 | 72.35 | 147.34 | 276.18 | 1.50 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
41.92 | -18.15 | -15.42 | -130.25 | 0.77 |
|
ROE (%)
|
1.43 | -28.46 | -18.95 | -106.84 | 3.39 |
|
ROA (%)
|
0.66 | -12.55 | -14.05 | -74.77 | 1.69 |
|
EBIT Margin (%)
|
-6.33 | -41.09 | -- | -- | 8.34 |
|
Net Margin (%)
|
3.26 | -41.86 | -593.92 | -- | 2.53 |
|
Cash Profit Margin (%)
|
-- | 0.00 | -- | -- | 0.00 |
Growth Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-8.81 | 5.10 | 1.91 | -1.00 | -99.61 |
|
EBIT Growth (%)
|
-76.55 | 11.36 | -- | -45.21 | 523.06 |
|
Net Profit Growth (%)
|
-96.17 | 11.44 | -16.13 | -43.04 | -99.68 |
|
EPS Growth (%)
|
-96.17 | -1.87 | -0.02 | 7.30 | -96.78 |
|
Book Value Growth (%)
|
2.54 | -25.05 | -- | 108.85 | 7.71 |
Valuation Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
5.08 | -11.11 | -13.58 | -9.99 | 469.58 |
|
Price / Book Value
|
1.88 | 2.73 | 2.32 | 8.70 | 4.83 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-25.58 | -9.39 | -18.38 | -9.30 | 36.65 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.21 | 0.00 | 0.34 |
|
Short term debt to equity ratio
|
0.02 | 0.40 | 0.10 | 0.09 | 0.03 |
|
Current Ratio
|
5.64 | 2.13 | 1.99 | 3.72 | 3.01 |
|
Quick Ratio
|
5.50 | 1.92 | 1.77 | 3.72 | 2.31 |
|
Interest Coverage
|
-19.05 | -30.87 | -3.49 | -- | 2.08 |
Operating Efficiency Ratios
| HUTCHMED (China) - ADR | Zai Lab - ADR | Mesoblast - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.41 | 16.23 | 86.44 | -- | 15.55 |
|
Asset Turnover
|
0.20 | 0.30 | 0.02 | 0.00 | 0.67 |
|
Receivable days
|
104.79 | 77.60 | 380.35 | -- | 51.78 |
|
Inventory Days
|
49.57 | 109.55 | 791.94 | -- | 492.02 |
|
Payable days
|
47.68 | 231.78 | 931.00 | 650.68 | 466.91 |
|
Cash Conversion Cycle
|
106.67 | -44.63 | 241.30 | -- | 76.89 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
